Prof. Dr. Peter Brossart
Medical Clinic III for Haematology and Oncology
peter.brossart@ukbonn.de View member: Prof. Dr. Peter Brossart
Clinical cancer research : an official journal of the American Association for Cancer Research
The introduction and the unexpected efficacy of checkpoint inhibitors (CPI) and more recently of chimeric antigen receptor T cells (CAR T-cells) in the treatment of malignant diseases boosted the efforts in the development and clinical application of immunotherapeutic approaches. However, the definition of predictive factors associated with clinical responses as well as the identification of underlying mechanisms that promote the therapeutic efficacy remain to be determined. Starting from the first immunotherapeutic trials, it became evident that vaccine-induced tumor-specific T cells or the adoptive transfer of -expanded T lymphocytes can recognize and eliminate malignant cells leading to long-lasting remissions in some patients. In addition, a phenomenon called epitope spreading, which was observed in responding patients, seemed to increase the efficiency possibly representing an important predictive factor. This review will focus on experimental and clinical evidence for the induction of epitope spreading and its role in the maintenance of an efficient antitumor immune response in cancer immunotherapy.
©2020 American Association for Cancer Research.
PMID: 32357962
Medical Clinic III for Haematology and Oncology
peter.brossart@ukbonn.de View member: Prof. Dr. Peter Brossart